Skip to main content

Table 2 Study efficacy outcome measures

From: Repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depression (TRMD) Veteran patients: study protocol for a randomized controlled trial

Outcomes Metric scale Schedule
Primary outcome Hamilton Rating Scale for Depression (HRSD) 24-Item instrument with overall score range of 0–76 Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
Secondary outcomes Montgomery-Asberg Depression Rating Scale (MADRS) 10-Item instrument with overall score range of 0–60 Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
Beck Depression Inventory (BDI) 21-Item self-report test with overall score range of 0–63 Measured at screening phase as baseline, end of each acute treatment week, and end of every 4 weeks during the follow-up phase
Beck Scale for Suicide Ideation (BSS) 21-Item self-report test with overall score range of 0–38 with last 2 items not counted in scoring Measured at screening phase as baseline, end of each acute treatment week, end of each taper week and week 4, and end of every 4 weeks during the follow-up phase
Veterans RAND 36-Item Health Survey (VR-36) A self-administered survey consisting of two parts, i.e. Physical Component Summary (PCS, standardized score range of 0–100) and Mental Component Summary (MCS, standardized score range of 0–100) Measured at screening phase as baseline, end of the acute treatment phase, and end of the follow-up phase
Neuropsychological Battery A cognitive function test including measures of executive function, attention, memory, visuospatial ability, processing speed, psychomotor function, and premorbid intelligence Measured at screening phase as baseline, end of the acute treatment phase, and end of the follow-up phase